ISGLT2 in Patients Without DM With Acute MI
NCT06903754 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 450
Last updated 2025-09-15
Summary
This study will evaluate the effect of ISGLT2 (Dapagliflozin or Empalgliflozin), administered once daily in addition to standard of care treatments for non-diabetic patients with myocardial infarction (MI) treated with PCI, on hospitalization for heart failure, readmissions for acute coronary syndrome and all-cause mortality.
Conditions
- Acute Coronary Syndromes
- Heart Failure
Interventions
- DRUG
-
With ISGLT2
Patients for whom we will prescribe ISGLT2
Sponsors & Collaborators
-
Mohammed VI University Hospital
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-01
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
- FDA Drug
- Yes
Countries
- Morocco
More Related Trials
-
Dapagliflozin in the Treatment of Heart Failure
NCT05727423 ·Status: ACTIVE_NOT_RECRUITING
-
Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
NCT05957887 ·Status: RECRUITING ·Phase: PHASE3
-
SGLT2i As Anti Arrhythmic Therapy to Prevent Sudden Cardiac Deaths.
NCT03366181 ·Status: COMPLETED
-
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
NCT05776043 ·Status: RECRUITING ·Phase: PHASE3
-
Use of SGLT2i in noHCM With HFpEF
NCT06401343 ·Status: RECRUITING ·Phase: PHASE4
-
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
NCT05764057 ·Status: RECRUITING ·Phase: PHASE3
-
EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
NCT05020704 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
NCT06065280 ·Status: COMPLETED ·Phase: NA
-
Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
NCT05424315 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
NCT03087773 ·Status: COMPLETED ·Phase: PHASE3
-
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
NCT04509674 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction
NCT06964607 ·Status: COMPLETED
-
Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.
NCT04564742 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction
NCT06619600 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients
NCT07186153 ·Status: NOT_YET_RECRUITING
-
Empagliflozin on Patients With Preserved Heart Failure
NCT07112274 ·Status: COMPLETED ·Phase: NA
-
Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
NCT05600387 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
NCT03036124 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction
NCT05045274 ·Status: UNKNOWN ·Phase: NA
-
Effect of Empagliflozin on Ventricular Repolarization.
NCT04117763 ·Status: COMPLETED ·Phase: PHASE4
-
SGLT2i and Incretin and CRTd.
NCT03282136 ·Status: COMPLETED ·Phase: PHASE4
-
Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function Performance
NCT06090487 ·Status: COMPLETED ·Phase: NA
-
Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.
NCT05911724 ·Status: COMPLETED
-
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
NCT06111768 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Effects of Dapagliflozin on Cardiorespiratory Parameters in Heart Failure
NCT05770167 ·Status: UNKNOWN